Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01507428 · ClinicalTrials.gov registry record · Phase 2
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT01507428: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01507428 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 138 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01507428, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans, to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor and cause less damage to healthy tissue.
Interventions
- DRUG Carboplatin
- PROCEDURE Computed Tomography
- RADIATION External Beam Radiation Therapy
- DRUG 18F-Fluoromisonidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2012-02-22 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01507428
The ClinicalTrials.gov registry entry for NCT01507428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01507428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01507428 about?
NCT01507428 is a clinical study titled "Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer". This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor ce...
What is the current status of trial NCT01507428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2012-02-22. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT01507428?
The interventions under investigation include: Carboplatin (DRUG), Computed Tomography (PROCEDURE), External Beam Radiation Therapy (RADIATION), 18F-Fluoromisonidazole (DRUG).
Who is sponsoring clinical trial NCT01507428?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.